Patent details
EP4058805 Title: ANTI-CLEVER-1 AGENTS FOR CONTROLLING THE EXPRESSION OF CELL SURFACE MARKERS ON LEUCOCYTES, AND USING THESE TO GUIDE ANTI-CLEVER-1 BASED CANCER TREATMENT
Basic Information
- Publication number:
- EP4058805
- PCT Application Number:
- FI2020050741
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP208116996
- PCT Publication Number:
- WO2021094652
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- ANTI-CLEVER-1 AGENTS FOR CONTROLLING THE EXPRESSION OF CELL SURFACE MARKERS ON LEUCOCYTES, AND USING THESE TO GUIDE ANTI-CLEVER-1 BASED CANCER TREATMENT
- French Title of Invention:
- AGENTS ANTI-CLEVER-1 POUR RÉGULER L'EXPRESSION DE MARQUEURS DE SURFACE CELLULAIRE SUR DES LEUCOCYTES, ET UTILISATION DE CEUX-CI POUR GUIDER UN TRAITEMENT DU CANCER À BASE D'ANTI-CLEVER-1
- German Title of Invention:
- ANTI-CLEVER-1-WIRKSTOFFE ZUR KONTROLLE DER EXPRESSION VON ZELLOBERFLÄCHENMARKERN AUF LEUKOZYTEN UND VERWENDUNG DIESER MITTEL ZUR ANLEITUNG EINER KREBSBEHANDLUNG AUF ANTI-CLEVER-1-BASIS
- SPC Number:
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 08/10/2024
- Link to UPP Register:
- European Patent Register
- Unitary Effect Request Withdrawal Date:
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 28/10/2024
- Unitary Effect Rejection Decision Date:
- Unitary Effect Date:
- 02/10/2024
- Unitary Effect Registration Date:
- 28/10/2024
- Unitary Effect Re-establishment of rights Filing Date:
- Unitary Effect Re-establishment of rights EPO Decision :
- Unitary Effect Re-establishment of rights EPO Decision Date:
- Explanatory Text UE:
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
Dates
- Filing date:
- 10/11/2020
- Grant date:
- 02/10/2024
- EP Publication Date:
- 21/09/2022
- PCT Publication Date:
- 20/05/2021
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 02/10/2024
- EP B1 Publication Date:
- 02/10/2024
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 10/11/2040
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 25/09/2024
- Name:
- Faron Pharmaceuticals OY
- Address:
- Joukahaisenkatu 6, 20520 Turku, Finland (FI)
Inventor
1
- Name:
- VIRTAKOIVU, Reetta
- Address:
- Finland (FI)
2
- Name:
- HOLLMÉN, Maija-Leena
- Address:
- Finland (FI)
3
- Name:
- JALKANEN, Juho
- Address:
- Finland (FI)
4
- Name:
- MANDELIN, Jami
- Address:
- Finland (FI)
5
- Name:
- VAURA, Felix
- Address:
- Finland (FI)
Priority
- Priority Number:
- 20195959
- Priority Date:
- 11/11/2019
- Priority Country:
- Finland (FI)
Classification
- IPC classification:
- G01N 33/574;
Publication
European Patent Bulletin
1
- Issue number:
- 202440
- Publication date:
- 02/10/2024
- Description:
- Grant (B1)
2
- Issue number:
- 202446
- Publication date:
- 13/11/2024
- Description:
- Unitary Effect Request Receipt
3
- Issue number:
- 202448
- Publication date:
- 27/11/2024
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|